| Perspective |  |
Open Access |
Other Countries Are Not Paying Their Fair Share of the Cost of Biopharmaceutical Innovation – What Can the United States Do to Change That?
|
|
|
||
Downloads |
Comments |
Views |
|
Introduction |
|
|
Understanding the Roots of the Problem |
|
|
What a Country Pays Should Reflect Its Ability to Pay, Not Its Willingness to Pay |
|
|
International Reference Pricing, including a “Most Favored Nation” Drug Pricing Model, would be disastrous for the U.S. |
|
|
Trade Negotiations Happening Now Present an Opportunity for the U.S. Government to Ensure Other Developed Countries Pay Their Fair Share for Biopharmaceutical Innovation |
|
|
A More Equitable System |
|
|
References |
Peer Reviews
